ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
ryan4321
|
1.3K |
540K |
1 |
02/08/23 |
02/08/23 |
ASX - By Stock
|
1.3K
|
540K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
ryan4321
|
1.3K |
540K |
13 |
02/08/23 |
02/08/23 |
ASX - By Stock
|
1.3K
|
540K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
ryan4321
|
1.3K |
540K |
4 |
02/08/23 |
02/08/23 |
ASX - By Stock
|
1.3K
|
540K
|
4
|
|
ASX - By Stock
|
BRN |
Re:
2022 BRN Discussion
|
|
ryan4321
|
10K |
4.7M |
8 |
22/01/22 |
22/01/22 |
ASX - By Stock
|
10K
|
4.7M
|
8
|
|
ASX - By Stock
|
A2B |
Re:
Ann: Change in substantial holding from SNC
|
|
ryan4321
|
1 |
635 |
0 |
21/12/21 |
21/12/21 |
ASX - By Stock
|
1
|
635
|
0
|
|
ASX - By Stock
|
A2B |
Re:
Expect a rerate
|
|
ryan4321
|
46 |
11K |
0 |
22/10/21 |
22/10/21 |
ASX - By Stock
|
46
|
11K
|
0
|
|
ASX - By Stock
|
A2B |
Re:
Expect a rerate
|
|
ryan4321
|
46 |
11K |
0 |
31/08/21 |
31/08/21 |
ASX - By Stock
|
46
|
11K
|
0
|
|
ASX - By Stock
|
A2B |
Re:
Expect a rerate
|
|
ryan4321
|
46 |
11K |
0 |
30/08/21 |
30/08/21 |
ASX - By Stock
|
46
|
11K
|
0
|
|
ASX - By Stock
|
A2B |
Re:
Expect a rerate
|
|
ryan4321
|
46 |
11K |
1 |
30/08/21 |
30/08/21 |
ASX - By Stock
|
46
|
11K
|
1
|
|
ASX - By Stock
|
A2B |
Re:
Expect a rerate
|
|
ryan4321
|
46 |
11K |
0 |
28/08/21 |
28/08/21 |
ASX - By Stock
|
46
|
11K
|
0
|
|
ASX - By Stock
|
A2B |
Re:
Expect a rerate
|
|
ryan4321
|
46 |
11K |
0 |
26/08/21 |
26/08/21 |
ASX - By Stock
|
46
|
11K
|
0
|
|
ASX - By Stock
|
A2B |
Re:
Expect a rerate
|
|
ryan4321
|
46 |
11K |
0 |
26/08/21 |
26/08/21 |
ASX - By Stock
|
46
|
11K
|
0
|
|
ASX - By Stock
|
BRN |
Re:
2021 BRN Discussion
|
|
ryan4321
|
33K |
11M |
5 |
09/08/21 |
09/08/21 |
ASX - By Stock
|
33K
|
11M
|
5
|
|
ASX - By Stock
|
A2B |
Continued Decline
|
|
ryan4321
|
0 |
363 |
1 |
30/06/21 |
30/06/21 |
ASX - By Stock
|
0
|
363
|
1
|
|
ASX - By Stock
|
A2B |
Re:
Expect a rerate
|
|
ryan4321
|
46 |
11K |
0 |
20/04/21 |
20/04/21 |
ASX - By Stock
|
46
|
11K
|
0
|
|
ASX - By Stock
|
A2B |
Re:
Expect a rerate
|
|
ryan4321
|
46 |
11K |
0 |
09/04/21 |
09/04/21 |
ASX - By Stock
|
46
|
11K
|
0
|
|
ASX - By Stock
|
A2B |
Re:
Expect a rerate
|
|
ryan4321
|
46 |
11K |
0 |
30/03/21 |
30/03/21 |
ASX - By Stock
|
46
|
11K
|
0
|
|
ASX - By Stock
|
A2B |
Re:
Expect a rerate
|
|
ryan4321
|
46 |
11K |
0 |
30/03/21 |
30/03/21 |
ASX - By Stock
|
46
|
11K
|
0
|
|
ASX - By Stock
|
A2B |
Re:
Expect a rerate
|
|
ryan4321
|
46 |
11K |
2 |
30/03/21 |
30/03/21 |
ASX - By Stock
|
46
|
11K
|
2
|
|
ASX - By Stock
|
A2B |
Re:
Ann: S&P DJI Announces March 2021 Quarterly Rebalance
|
|
ryan4321
|
2 |
587 |
0 |
30/03/21 |
30/03/21 |
ASX - By Stock
|
2
|
587
|
0
|
|
ASX - By Stock
|
BRN |
Re:
BRN Share Price prediction by 25/12/2021
|
|
ryan4321
|
828 |
310K |
4 |
16/03/21 |
16/03/21 |
ASX - By Stock
|
828
|
310K
|
4
|
|
ASX - By Stock
|
A2B |
Re:
Expect a rerate
|
|
ryan4321
|
46 |
11K |
1 |
01/03/21 |
01/03/21 |
ASX - By Stock
|
46
|
11K
|
1
|
|
ASX - By Stock
|
A2B |
Re:
Expect a rerate
|
|
ryan4321
|
46 |
11K |
1 |
01/03/21 |
01/03/21 |
ASX - By Stock
|
46
|
11K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
|
|
ryan4321
|
1.1K |
308K |
8 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
1.1K
|
308K
|
8
|
|
ASX - By Stock
|
A2B |
Re:
Ann: Director Appointment/Resignation
|
|
ryan4321
|
8 |
2.9K |
0 |
10/02/21 |
10/02/21 |
ASX - By Stock
|
8
|
2.9K
|
0
|
|
ASX - By Stock
|
SYR |
Re:
Graphite Price
|
|
ryan4321
|
1.1K |
510K |
0 |
27/01/21 |
27/01/21 |
ASX - By Stock
|
1.1K
|
510K
|
0
|
|
ASX - By Stock
|
KLA |
Re:
KLA Riding High in the Saddle
|
|
ryan4321
|
2 |
1.8K |
0 |
12/01/21 |
12/01/21 |
ASX - By Stock
|
2
|
1.8K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
ryan4321
|
17K |
6.5M |
20 |
12/01/21 |
12/01/21 |
ASX - By Stock
|
17K
|
6.5M
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Healthcare Conference Investor Presentation
|
|
ryan4321
|
73 |
41K |
0 |
12/01/21 |
12/01/21 |
ASX - By Stock
|
73
|
41K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Healthcare Conference Investor Presentation
|
|
ryan4321
|
73 |
41K |
2 |
12/01/21 |
12/01/21 |
ASX - By Stock
|
73
|
41K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
ryan4321
|
796 |
391K |
55 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
391K
|
55
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
ryan4321
|
796 |
391K |
20 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
391K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
ryan4321
|
1.0K |
415K |
6 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
1.0K
|
415K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Corporate Update Webcast
|
|
ryan4321
|
125 |
54K |
5 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
125
|
54K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
ryan4321
|
13K |
4.9M |
4 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
ryan4321
|
572 |
250K |
0 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
572
|
250K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
ryan4321
|
572 |
250K |
3 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
572
|
250K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
ryan4321
|
572 |
250K |
1 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
572
|
250K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
ryan4321
|
572 |
250K |
3 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
572
|
250K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
ryan4321
|
572 |
250K |
5 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
572
|
250K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
ryan4321
|
572 |
250K |
13 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
572
|
250K
|
13
|
|
ASX - By Stock
|
SYR |
Re:
Ann: Syrah confirm robust economics for anode production in USA
|
|
ryan4321
|
95 |
36K |
3 |
01/12/20 |
01/12/20 |
ASX - By Stock
|
95
|
36K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
ryan4321
|
13K |
4.9M |
17 |
28/11/20 |
28/11/20 |
ASX - By Stock
|
13K
|
4.9M
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
ryan4321
|
811 |
330K |
7 |
28/11/20 |
28/11/20 |
ASX - By Stock
|
811
|
330K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
ryan4321
|
811 |
330K |
3 |
23/11/20 |
23/11/20 |
ASX - By Stock
|
811
|
330K
|
3
|
|
ASX - By Stock
|
A2B |
Re:
Ann: Director Appointment/Resignation
|
|
ryan4321
|
8 |
2.9K |
0 |
23/11/20 |
23/11/20 |
ASX - By Stock
|
8
|
2.9K
|
0
|
|
ASX - By Stock
|
A2B |
Re:
Ann: Director Appointment/Resignation
|
|
ryan4321
|
8 |
2.9K |
0 |
23/11/20 |
23/11/20 |
ASX - By Stock
|
8
|
2.9K
|
0
|
|
ASX - By Stock
|
A2B |
Re:
Ann: Director Appointment/Resignation
|
|
ryan4321
|
8 |
2.9K |
0 |
23/11/20 |
23/11/20 |
ASX - By Stock
|
8
|
2.9K
|
0
|
|
ASX - By Stock
|
A2B |
Re:
Ann: Final Director's Interest Notice - Richard Millen
|
|
ryan4321
|
2 |
563 |
0 |
23/11/20 |
23/11/20 |
ASX - By Stock
|
2
|
563
|
0
|
|
ASX - By Stock
|
A2B |
Re:
Ann: Results of Meeting
|
|
ryan4321
|
2 |
570 |
0 |
23/11/20 |
23/11/20 |
ASX - By Stock
|
2
|
570
|
0
|
|